This expected relief may benefit from multiple factors: For example, novel drugs such as IL-23p19 antibodies (e.g., guselkumab and risankizumab) and JAK inhibitors (e.g., upadacitinib) have been able to better control inflammatory responses and reduce disease recurrence by more precisely targeting inflammatory mediators, thereby lowering the prevalence of IBD and even the mortality rate of severe active IBD [64]. Here, IL23A is linked to inflammatory bowel disease.